Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nucana ( (NCNA) ) just unveiled an announcement.
On August 1, 2025, NuCana announced a change in the ratio of its American Depositary Shares (ADS) to ordinary shares, from one ADS representing 25 shares to one ADS representing 5,000 shares. This adjustment, effective August 11, 2025, is akin to a one-for-two-hundred reverse ADS split and aims to enhance liquidity and compliance with Nasdaq’s minimum bid price requirement. The change will not affect the proportional equity interest of ADS holders but may impact the trading price and liquidity of the ADSs.
The most recent analyst rating on (NCNA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Nucana stock, see the NCNA Stock Forecast page.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, focused on enhancing cancer treatment outcomes through its ProTide technology. The company aims to transform widely used chemotherapy agents into more effective and safer medicines, addressing the limitations of conventional nucleoside analogs. NuCana’s pipeline includes promising candidates like NUC-7738 and NUC-3373, which are in various stages of clinical trials for treating advanced solid tumors and lung cancer.
Average Trading Volume: 243,855,035
Technical Sentiment Signal: Sell
Current Market Cap: $16.37M
For detailed information about NCNA stock, go to TipRanks’ Stock Analysis page.